Concordant with this idea, other AD biomarkers have shown hypometabolism, along with hippocampal atrophy, to succeed changes in CSF amyloid B levels and tau deposition in a stage-dependent manner50,51. The gene discussed is MAPT; the disease is hippocampal atrophy.